The Role of Prophylactic Surgery in Cancer Prevention

You, Y. Nancy; Lakhani, Vipul T.; Wells Jr., Samuel A.
March 2007
World Journal of Surgery;Mar2007, Vol. 31 Issue 3, p450
Academic Journal
Since the human genome has been sequenced many mysteries of cell biology have been unravelled, thereby clarifying the pathogenesis of several diseases, particularly cancer. In members of kindreds with certain hereditary diseases, it is now possible early in life to predict with great certainty whether or not a family member has inherited the mutated allele causing the disease. In hereditary malignancies this has been particularly important, because in affected family members there is the possibility of removing the organ destined to develop cancer before malignancy develops or while it is in situ. At first consideration, it would appear that “prophylactic surgery” would have a place in many hereditary malignancies; however, the procedure has applicability only if certain criteria are met: (1) the genetic mutation causing the hereditary malignancy must have a very high penetrance and be expressed regardless of environmental factors; (2) there must be a highly reliable test to identify patients who have inherited the mutated gene; (3) the organ must be removed with minimal morbidity and virtually no mortality; (4) there must be a suitable replacement for the function of the removed organ; and (5) there must be a reliable method of determining over time that the patient has been cured by “prophylactic surgery.” In this monograph we review several hereditary malignancies and consider those where prophylactic surgery might be useful. As we learn, there are various barriers to performing the procedure in many common hereditary cancer syndromes. The archetype disease syndromes, which meet each of the five criteria mentioned above and where prophylactic surgery is most useful, are the type 2 multiple endocrine neoplasia (MEN) syndromes: MEN2A, MEN2B, and the related familial medullary thyroid carcinoma. An additional benefit of the Human Genome Project, has been the development of pharmacologic and biologic compounds that block the metabolic pathway(s) activated by specific genetic mutations. Many of these compounds have shown efficacy in patients with locally advanced or metastatic cancers, and there is the likelihood that they will prove beneficial in preventing the outgrowth of malignant cells in patients destined to develop a hereditary cancer.


Related Articles

  • The Complexities of Epidemiology and Prevention of Gastrointestinal Cancers. Haq, Saba; Ali, Shadan; Mohammad, Ramzi; Sarkar, Fazlul H. // International Journal of Molecular Sciences;Oct2012, Vol. 13 Issue 10, p12556 

    Cancer epidemiology and prevention is one of the most well studied fields today. The more we can understand about the incidence and pathogenesis of this disease, the better we will be able to prevent it. Effective prevention strategies can decrease the mortality rate of cancer significantly;...

  • A complex V ATP5A1 defect causes fatal neonatal mitochondrial encephalopathy. Jonckheere, An I.; Renkema, G. Herma; Bras, Maaike; van den Heuvel, Lambert P.; Hoischen, Alexander; Gilissen, Christian; Nabuurs, Sander B.; Huynen, Martijn A.; de Vries, Maaike C.; Smeitink, Jan A.M.; Rodenburg, Richard J.T. // Brain: A Journal of Neurology;May2013, Vol. 136 Issue 5, p1544 

    Whole exome sequencing is a powerful tool to detect novel pathogenic mutations in patients with suspected mitochondrial disease. However, the interpretation of novel genetic variants is not always straightforward. Here, we present two siblings with a severe neonatal encephalopathy caused by...

  • Genome-Wide Association Studies (GWAS) in Complex Diseases: Advantages and Limitations. Riancho, José A. // Reumatologia Clinica;mar/abr2012, Vol. 8 Issue 2, p56 

    No abstract available.

  • Experimental Anti-Cancer Drugs Show Promise for Treating Progeria. N. O. // Access;Dec2005, Vol. 19 Issue 10, p44 

    The article reports on the discovery of a class of experimental anti-cancer drugs, which can be used for treating Hutchinson-Gilford Progeria Syndrome. The class of the drugs was discovered by a research team from the National Human Genome Research Institute. Progeria is a genetic disorder. One...

  • Basic concepts of medical genetics, pathogenetics, part 5. Zaghloul Salem, Mohammad Saad // Egyptian Journal of Medical Human Genetics;2013, Vol. 14 Issue 4, p429 

    The article discusses the pathogenetic mechanisms of genetic diseases and anti-mutation mechanisms of human proteome and genome. It cites the pathophysiological alterations and pathogenetic mechanisms concerned in the pathogenesis of genetic diseases that may lead to diseases. It also notes that...

  • Finnish Disease Heritage I:. Norio, Reijo // Human Genetics;May2003, Vol. 112 Issue 5/6, p441 

    This review of the Finnish Disease Heritage (FDH), a group of rare hereditary diseases that are overrepresented in Finland, includes the following topics: FDH characteristics, causes and background, primary theory, revis(it)ed theory, consanguineous marriages in Finland, internal migration of...

  • Evolutionary anatomies of positions and types of disease-associated and neutral amino acid mutations in the human genome. Subramanian, Sankar; Kumar, Sudhir // BMC Genomics;2006, Vol. 7, p306 

    Background: Amino acid mutations in a large number of human proteins are known to be associated with heritable genetic disease. These disease-associated mutations (DAMs) are known to occur predominantly in positions essential to the structure and function of the proteins. Here, we examine how...

  • The Human Genome Project - an opportunity for improved fetal and infant health. Williamson, R. // Reproductive BioMedicine Online (Reproductive Healthcare Limited;2002 Supplement 2, Vol. 4 Issue S2, p10 

    The Human Genome Project is now complete. Gene analysis for mutations that cause serious single-gene disorders and for aneuploidy can be carried out on single cells. Most couples will avoid the birth of a child with severe handicap if possible. However. the organizational strategies required to...

  • Missense and splice site mutations in SPG4 suggest loss-of-function in dominant spastic paraplegia. Patrono, Clarice; Casali, Carlo; Tessa, Alessandra; Cricchi, Federica; Fortini, Daniela; Carrozzo, Rosalba; Siciliano, Gabriele; Bertini, Enrico; Santorelli, Filippo M. // Journal of Neurology;Feb2002, Vol. 249 Issue 2, p200 

    We studied nine Italian families with a pure form of autosomal dominant spastic paraplegia (ADHSP) to assess the frequency of mutations in the SPG4 gene. We observed marked intrafamilial variability in both age-at-onset and clinical severity, ranging from severe congenital presentation to mild...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics